氯喹和羟氯喹在冠状病毒病-19（COVID-19）中的预防作用的系统评价。
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
机构信息
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
出版信息
Int J Rheum Dis. 2020 May;23(5):613-619. doi: 10.1111/1756-185X.13842. Epub 2020 Apr 27.
OBJECTIVE
The pandemic coronavirus disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19.
METHODS
PubMed, EMBASE, ClinicalTrials.gov, International Clinical Trials Registry Platform and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised.
RESULTS
A total of 45 articles were screened and 5 (3 in vitro pre-clinical studies and 2 clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available.
CONCLUSION
Although pre-clinical results are promising, to date there is a dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high-quality randomized controlled studies.
目的
大流行的冠状病毒病-19（COVID-19）使全球医疗体系陷入危机，造成了巨大的经济负担。人们尝试了多种预防 COVID-19 的药物，包括氯喹（CQ）或羟氯喹（HCQ）。本研究旨在系统地评估 CQ 和 HCQ 在预防 COVID-19 传播中的作用。
方法
检索了 PubMed、EMBASE、ClinicalTrials.gov、国际临床试验注册平台和 Cochrane 图书馆数据库，以评估 CQ 或 HCQ 在预防 SARS-CoV-2（临床前研究）或 COVID-19（临床研究）中的作用，检索截至 2020 年 3 月 30 日。对现有文献进行了严格评价。
结果
共筛选出 45 篇文章，其中 5 篇（3 篇临床前研究和 2 篇临床意见）被纳入。临床前研究显示 CQ 和 HCQ 对 SARS-CoV-2 具有预防作用。另一方面，临床意见主张预防性使用 CQ 和 HCQ 来预防 COVID-19。然而，目前尚无关于 CQ 或 HCQ 预防 COVID-19 的临床研究。
结论
尽管临床前结果令人鼓舞，但迄今为止，尚无证据支持 CQ 或 HCQ 预防 COVID-19 的疗效。考虑到潜在的安全问题和产生虚假安全感的可能性，需要在观察性研究或高质量随机对照研究中对 CQ 或 HCQ 预防 COVID-19 的作用进行彻底评估。
Zotero 插件